Jump Financial LLC Takes $211,000 Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Jump Financial LLC bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 15,160 shares of the company’s stock, valued at approximately $211,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Investment Counsel Co. of Nevada purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth about $1,182,000. Barclays PLC grew its stake in shares of Tyra Biosciences by 14.5% during the fourth quarter. Barclays PLC now owns 43,070 shares of the company’s stock worth $599,000 after acquiring an additional 5,445 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth about $761,000. Renaissance Technologies LLC purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth about $404,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Tyra Biosciences by 130,587.5% during the fourth quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company’s stock worth $145,000 after acquiring an additional 10,447 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares in the company, valued at $6,107,857.60. This represents a 1.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.40% of the stock is currently owned by corporate insiders.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $10.04 on Monday. The stock has a market capitalization of $533.02 million, a P/E ratio of -6.24 and a beta of 1.19. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The company has a 50 day moving average price of $10.03 and a 200 day moving average price of $14.21.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. Research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TYRA shares. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences has an average rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.